Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael E Abram

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Plos One|February 18, 2017
Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcomeMichael E Abram, Renee R Ram, Nicolas A Margot, et al.
Journal of Virology|April 25, 2014
Mutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replicationMichael E Abram, Andrea L Ferris, Kalyan Das, et al.
HIV Clinical Trials|October 29, 2014
Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patientsRima Kulkarni, Michael E Abram, Damian J McColl, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 28, 2016
Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 StudyFrank A Post, Pablo Tebas, Amanda Clarke, et al.
HIV Clinical Trials|March 18, 2017
Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial<sup/>Frank A Post, Yazdan Yazdanpanah, Gabriel Schembri, et al.
Nature Medicine|April 24, 2023
Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infantsDeidre Wilkins, Yuan Yuan, Yue Chang, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 4, 2014
Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairmentFrank A Post, Jonathan Winston, Jaime F Andrade-Villanueva, et al.
HIV Clinical Trials|December 1, 2014
Cobicistat-boosted protease inhibitors in HIV-infected patients with mild to moderate renal impairmentCheryl K McDonald, Claudia Martorell, Moti Ramgopal, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 17, 2015
Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 ResultsJoel E Gallant, Ellen Koenig, Jaime F Andrade-Villanueva, et al.
Journal of Clinical Microbiology|October 22, 2020
Global Molecular Epidemiology of Respiratory Syncytial Virus from the 2017-2018 INFORM-RSV StudyDavid E Tabor, Fiona Fernandes, Annefleur C Langedijk, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Plos One|February 18, 2017
Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcomeMichael E Abram, Renee R Ram, Nicolas A Margot, et al.
Journal of Virology|April 25, 2014
Mutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replicationMichael E Abram, Andrea L Ferris, Kalyan Das, et al.
HIV Clinical Trials|October 29, 2014
Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patientsRima Kulkarni, Michael E Abram, Damian J McColl, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 28, 2016
Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 StudyFrank A Post, Pablo Tebas, Amanda Clarke, et al.
HIV Clinical Trials|March 18, 2017
Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial<sup/>Frank A Post, Yazdan Yazdanpanah, Gabriel Schembri, et al.
Nature Medicine|April 24, 2023
Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infantsDeidre Wilkins, Yuan Yuan, Yue Chang, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 4, 2014
Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairmentFrank A Post, Jonathan Winston, Jaime F Andrade-Villanueva, et al.
HIV Clinical Trials|December 1, 2014
Cobicistat-boosted protease inhibitors in HIV-infected patients with mild to moderate renal impairmentCheryl K McDonald, Claudia Martorell, Moti Ramgopal, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 17, 2015
Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 ResultsJoel E Gallant, Ellen Koenig, Jaime F Andrade-Villanueva, et al.
Journal of Clinical Microbiology|October 22, 2020
Global Molecular Epidemiology of Respiratory Syncytial Virus from the 2017-2018 INFORM-RSV StudyDavid E Tabor, Fiona Fernandes, Annefleur C Langedijk, et al.
Pageof 4